Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
IMUX Stock Chart & Stats
$0.75
-$0.01(-1.34%)
At close: 4:00 PM EST
$0.75
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$0.56 - $1.42
Previous CloseN/A
Volume261.21K
Average Volume (3M)1.56M
Market Cap
$68.18M
Enterprise Value$37.86M
Total Cash (Recent Filing)$55.31M
Total Debt (Recent Filing)$979.00K
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 06, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding98,650,590
10 Day Avg. Volume1,304,997
30 Day Avg. Volume1,560,374
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue332.12
Enterprise Value/Gross Profit-1.31K
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$5.33Price Target Upside610.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe CALLIPER trial has shown reduced disability worsening in subpopulations without inflammatory lesions at baseline and reduced the annualized rate of thalamic brain volume loss compared to placebo.
Long-term SafetyVidofludimus calcium has remained safe and well-tolerated in RRMS patients for durations up to 5.5 years without new safety signals observed.
Market PositioningThere is significant interest in oral treatments for multiple sclerosis, with 40% of prescriptions being oral, which supports vidofludimus calcium's market positioning.
Bears Say
CompetitionThe upcoming competitor data from the PERSEUS study for the BTK inhibitor tolebrutinib in PPMS, despite its liver toxicity liabilities, could impact the competitive landscape.
Financial ConcernsLimited cash runway suggests the necessity for business development to unlock value.
Liquidity IssuesLiquidity is a going concern for Immunic.
Immunic News
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.56 and its highest was $1.42 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $68.18M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Nov 06, 2025 which is tomorrow.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Aug 07, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.042.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.14.
How many shares outstanding does Immunic have?
Immunic has 98,650,590 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went down -8.163%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.33 (610.67% Upside)
$5.33 (610.67% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.14%
12-Months-Change
Fundamentals
Return on Equity
-208.93%
Trailing 12-Months
Asset Growth
-28.98%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company's lead product candidate, IMU-838, is an orally available, selective immune modulator that targets diseases such as multiple sclerosis and inflammatory bowel disease. Immunic leverages its proprietary technology platforms to advance its pipeline of innovative therapies.
IMUX Stock 12 Month Forecast
Average Price Target
$5.33
▲(610.67% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
1.28% Insiders
5.12% Mutual Funds
0.01% Other Institutional Investors
89.78% Public Companies and Individual Investors